Hualan Biological Engineering, Inc. (A-share listed pharmaceutical company) announced on the evening of November 21 that its participating company, Hualan Genetic Engineering Co., Ltd. ("Hualan Genetic" for short), had obtained the "Drug Registration Certificate" for Bevacizumab Injection issued by the National Medical Products Administration, and was approved for formal production and sales. This is expected to become a new profit growth point for Hualan Biological Engineering, Inc.The announcement shows that Ambenu (Bevacizumab Injection), recently approved for Hualan Genetic, is mainly used to treat advanced, metastatic or recurrent non-small cell lung cancer, metastatic colorectal cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and cervical cancer.In 2023, the total sales of Bevacizumab Injection in China amounted to approximately 10.7 billion yuan, representing a 23.9% increase compared to 2022.Hualan Genetic was established in 2013 and mainly focuses on the research, development, and production of innovative drugs and biosimilars. The company has obtained clinical trial approvals for 10 products so far. Among them, four products—Adalimumab, Trastuzumab, Rituximab, and Denosumab—are in Phase III clinical trials; two products—Ipilimumab and Panitumumab—are in Phase I clinical trials; and three products, including Recombinant Anti-Claudin18.2 Fully Human Monoclonal Antibody Injection, are preparing to enter Phase I clinical trials.Pharmaceutical ResearchReportSharing CampCollecting and Sharing Mainstream Pharmaceutical Research Reports in the Entire Market
Only 0.8 yuan per day
EnjoyMore than 1900 articlesSelected Medical Research Reports
New additions in the next yearAdditional 500 Articles
